Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer OncLive 2:26 7 years ago 1 692 Далее Скачать
Dr. Shaw Discusses LDK378 and Alectinib (AF802) for ALK-Positive NSCLC OncLive 2:32 10 years ago 1 373 Далее Скачать
Dr. Shaw on LDK378 in ALK+ Crizotinib-Resistant NSCLC Patients Targeted Oncology 1:51 11 years ago 201 Далее Скачать
Alectinib eclipses crizotnib for ALK positive lung cancer ecancer 4:00 7 years ago 1 737 Далее Скачать
ALEX: alectinib is the best first-line therapy available for ALK-positive NSCLC VJOncology 1:56 6 years ago 2 262 Далее Скачать
Dr. Shaw Discusses the Advent of More Potent ALK Inhibitors Targeted Oncology 1:14 11 years ago 91 Далее Скачать
Dr. Shaw on Crizotinib in ALK-Positive Lung Cancer Targeted Oncology 1:58 11 years ago 518 Далее Скачать
Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC Targeted Oncology 3:04 7 years ago 596 Далее Скачать
Dr. Shaw on the Phase III Results of the ALEX Trial in NSCLC OncLive 1:35 7 years ago 327 Далее Скачать
Dr. Shaw on Crizotinib Versus Chemotherapy in ALK-Positive NSCLC Targeted Oncology 1:52 11 years ago 783 Далее Скачать
Dr. Alice Shaw Compares Crizotinib and Chemotherapy in NSCLC OncLive 1:42 11 years ago 435 Далее Скачать
Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC? GRACE - Global Resource for Advancing Cancer Education 4:14 9 years ago 68 Далее Скачать
